AN2 Therapeutics to Present New Data for Epetraborole at IDWeek 2023

AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and serious infectious diseases with high unmet needs, today announced two oral presentations and three poster presentations at the Infectious Disease Society of America (IDSA) IDWeek 2023 Conference from October 11-15, 2023 in Boston, Massachusetts. AN2 Therapeutics is currently enrolling patients in the Phase 3 part of its pivotal Phase 2/3 clinical trial evaluating once-daily, oral epetraborole for treatment-refractory Mycobacterium avium complex (MAC) lung disease.

“We are excited to showcase our latest data at IDWeek 2023. These results highlight epetraborole’s potent nonclinical activity against MAC isolates, as well as M. abscessus, another difficult-to-treat NTM pathogen. Additionally, epetraborole demonstrated favorable pharmacokinetics at the current dose in patients with various degrees of renal impairment and in Japanese subjects with different alcohol dehydrogenase genotypes, which further supports our dosing strategy in patients with treatment-refractory MAC lung disease,” said Paul Eckburg, M.D., Chief Medical Officer of AN2 Therapeutics. “These data, combined with results from our ongoing pivotal Phase 2/3 study — which is currently enrolling participants in the Phase 3 portion — are expected to provide the basis for regulatory filings for approval in the U.S. and Japan. We are enthusiastic about the progress we have achieved so far and look forward to advancing our mission to develop a novel therapy for patients with treatment-refractory MAC lung disease."

Oral presentations pertaining to epetraborole:

Title: Epetraborole: A Novel Antibiotic for NTM Lung Disease & Melioidosis
Session: New Antimicrobials in the Pipeline Part 1
Date: Thursday, October 12, 2023
Time: 8:48 AM – 9:00 AM ET
Room: 104ABC
Presentation # 32

Title: In Vitro Susceptibility of Recent Mycobacterium abscessus Isolates to Epetraborole (EBO) and Comparators by Broth Microdilution
Session: Experimental Therapeutics
Date: Saturday, October 14, 2023
Time: 10:54 AM – 11:06 AM ET
Location: 102AB
Presentation # 2064

Poster presentations pertaining to epetraborole:

Title: A Phase 1, Multicenter, Open-Label, Parallel-Group Study to Assess the Safety and Pharmacokinetics (PK) of Oral Epetraborole Tablets in Adult Subjects with Varying Degrees of Renal Function
Session: Antimicrobial Novel Agents
Date: Saturday, October 14, 2023
Time: 12:15 PM - 1:30 PM ET
Location: Hall B&C
Presentation # 2144

Title: A Phase 1, Open-Label, Single Dose Study to Evaluate the Pharmacokinetics (PK), Safety, and Tolerability of Epetraborole Tablets and the Impact of Alcohol Dehydrogenase (ADH) Genotype on the PK of Epetraborole and Metabolite M3 in Healthy Japanese Adult Subjects